– USA, MA – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced the appointment of Dr. George Golumbeski (Ph.D.) to its Board of Directors as Chairman, bringing more than 30 years of experience in the biopharmaceuticals industry, with extensive expertise in portfolio strategy, strategic collaborations and licensing, and M&A.
About Dr. George Golumbeski
Currently, Dr. Golumbeski is dedicated to helping develop young companies at DROIA Ventures, a specialist biotech investment firm. For nearly a decade, Dr. Golumbeski served as EVP of Business Development at Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medicines to people suffering from cancer and chronic inflammation. Before joining Celgene, Dr. Golumbeski held leadership positions in business development at Novartis Pharmaceuticals and Elan Pharmaceuticals. At Elan, he worked exclusively on neurology and neurodegeneration.
Dr. George Golumbeski holds a Ph.D. in Genetics from the University of Wisconsin-Madison, conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder, and holds a B.A. in Biology from the University of Virginia.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in people with early Alzheimer’s disease, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass.
For more information: https://acumenpharm.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.